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L-folinic acid versus folic acid for the treatment of hyperhomo- Elevated levels of plasma total homocysteine (tHcy),
cysteinemia in hemodialysis patients. the putatively atherothrombotic sulfur amino acid [1, 2],
Background. The hyperhomocysteinemia found in most he- are observed in at least 85% of patients with end-stage
modialysis patients is refractory to combined oral B-vitamin renal disease (ESRD) undergoing maintenance dialysissupplementation featuring supraphysiological doses of folic acid
[2]. The mild hyperhomocysteinemia characteristic of(FA). We evaluated whether a high-dose l-folinic acid-based
dialysis patients has proven largely refractory to pharma-regimen provided improved total homocysteine (tHcy)-lowering
efficacy in chronic hemodialysis patients, as suggested by a cological doses of folic acid (FA)-based B vitamin sup-
recent uncontrolled report. plementation [2, 3]. We reported earlier, for example,
Methods. We block-randomized 48 chronic, stable hemodi- that a final on treatment plasma tHcy ,12 mmol/L could
alysis patients based on their screening predialysis tHcy levels, be achieved in only one of 15 (6.7%) dialysis patients
sex, and dialysis center into two groups of 24 subjects treated
despite two months of supplementation with a total offor 12 weeks with oral FA at 15 mg/day or an equimolar amount
16 mg per day of FA, 110 mg per day of vitamin B6, and(20 mg/day) of oral l-folinic acid (FNA) [l-5-formyltetrahy-
1 mg per day of vitamin B12 [3].drofolate]. All 48 subjects also received 50 mg/day of oral
vitamin B6 and 1.0 mg/day of oral vitamin B12. Recent findings from an open-label, uncontrolled in-
Results. The mean percentage (%) reductions (with 95% CIs) vestigation suggested that high doses of the reduced fo-
in predialysis tHcy were not significantly different [FNA 5 late d,l-5-formyltetrahydrofolate [d,l-folinic acid (FNA)]
22.1% (11.8 to 31.4%), FA 5 20.7% (11.7 to 30.5%), P 5 might provide improved tHcy-lowering efficacy in pa-0.950 by paired t test]. Final on-treatment values (mean with
tients with end-stage renal disease (ESRD) undergoing95% CI) were as follows: FNA, 15.9 mmol/L (14.0 to 18.0);
maintenance hemodialysis [4]. In contrast, an additionalFA, 16.9 mmol/L (14.8 to 18.8). Moreover, in those subjects with
uncontrolled study of d,l-folinic acid failed to confirmbaseline tHcy levels $14 mmol/L, neither treatment resulted in
“normalization” of tHcy levels (that is, final on-treatment val- these findings (abstract; Bayes et al, J Am Soc Nephrol
ues ,12 mmol/L) among a significantly different or clinically 10:274A, 1999). Neither of these preliminary investiga-
meaningful number of patients [FNA 5 2 out of 22 (9.1%); tions involved a controlled, direct comparison of the
FA 5 2 out of 24 (8.3%); Fisher’s exact test of between groups tHcy-lowering efficacy of a reduced folate, versus folic
difference, P 5 1.000].
(pteroylglutamic) acid, among patients with ESRD (ab-Conclusions. Relative to high-dose FA, high-dose oral l-folinic
stract; Bayes et al, J Am Soc Nephrol 10:274A, 1999)acid-based supplementation does not afford improved tHcy-
[4]. Accordingly, we conducted a block randomized, con-lowering efficacy in hemodialysis patients. The preponderance
of hemodialysis patients (that is, .90%) exhibits mild hyperho- trolled comparison of oral treatment with either high-
mocysteinemia refractory to treatment with either regimen. dose l-folinic acid or FA, combined with oral vitamin
B6 and vitamin B12, on predialysis plasma tHcy levels
in 48 (that is, two matched groups of 24) maintenance
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nance hemodialysis.
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Table 1. Baseline characteristics by treatment group assayed from aliquots (which had been cryopreserved at
2708C) obtained during each of the four study visits.l-folinic acid Folic acid P valuea
Using tHcy data obtained from all 48 participants atN 24 24 —
Sex, N (% women) 10 (41.7%) 10 (41.7%) — the initial pretreatment screening, with 24 subjects block
Ageb years 60 (15) 64 (12) 0.383 randomized to each of the two groups, we estimated, a
[30–81] [36–82]
priori, that there was 86% power at a two-tailed a oftHcyc lmol/L 20.4 (19.0–21.8) 21.3 (19.9–22.7) 0.239
Folatec ng/mL 36.6 (28.0–45.2) 30.2 (22.7–37.7) 0.258 0.05 to detect a 4.5 mmol/L (that is, a clinically relevant)
PLPc nmol/mL 119.3 (77.4–161.2) 82.6 (55.7–109.5) 0.200 difference in the pretreatment to post-treatment change
B12c pg/mL 736 (563–910) 631 (554–709) 0.270
in tHcy comparing the l-folinic acid and FA treatmentCreatininec mg/dL 8.6 (6.9–10.3) 8.4 (7.2–9.6) 0.807
Albuminc mg/dL 3.8 (3.7–4.0) 3.7 (3.5–3.8) 0.549 groups [8].
All laboratory analyte values reported are based ona Based on paired t test or Fisher’s exact test
b Mean (standard deviation); [complete range] averages of two pretreatment and post-treatment values.
c Mean (95% confidence interval)
Descriptive statistics included arithmetic means (with
95% CIs), and frequencies (percentages). Baseline con-
tinuous variables were compared by paired t tests, and
categorical variables were compared by chi square analy-and all participants provided written informed consent.
sis. Continuous variables were assessed using both un-Participants were 48 chronic (that is, hemodialysis dura-
transformed and (natural log) transformed values. Treat-tion $6 months), stable hemodialysis patients free of
ment effects on percentage changes in tHcy levels weremalignancy, end-stage congestive heart failure, active
presented as [(average pretreatment level 2 averageliver or thyroid disease, uncontrolled diabetes, and clini-
post-treatment level) 4 average pretreatment level] 3cal malnutrition, whose serum albumin was $3.0 mg/dL.
100, and were compared by paired t tests. Overall compli-As per the standard of care for hemodialysis centers
ance with the study capsules was confirmed by assessingin Rhode Island, all patients were prescribed a daily
the mean increase (percentage change) in plasma PLPmultivitamin that contained 1.0 mg FA, 10.0 mg vitamin
and vitamin B12 levels among all 48 participants, usingB6, and 0.012 mg vitamin B12. This baseline supplementa-
paired t tests. Reported P values were based on two-tion regimen was continued throughout the 12-week in-
tailed calculations. All statistical analyses were per-vestigation. Study participants were matched in specific
formed by using SYSTAT software (version 9.0; SPSS,pairs on the basis of sex, dialysis center, and their screen-
Chicago, IL, USA).ing (initial) nonfasting, prehemodialysis tHcy levels (that
is, within #2 mmol/L; mean between pair difference 5
0.7 mmol/L). They were then randomly assigned in paired RESULTS
blocks to one of two treatment regimens: FA group-FA As depicted in Table 1, block randomization was suc-
15.0 mg/day, vitamin B6 50.0 mg/day, vitamin B12 1.0 mg/ cessful with respect to the key baseline covariables. All
day (N 5 24); l-folinic acid (FNA) group [l-5-formyltet- 48 patients completed the entire study protocol. Average
rahydrofolate] (Eprova, Zurich, Switzerland) 20.0 mg/ compliance by pill count was 90.0% (91.1% in the FNA
day (that is, equimolar to 15.0 mg/day FA), vitamin B6 group and 88.5% in the FA group), a finding confirmed
50.0 mg/day, vitamin B12 1.0 mg/day (N 5 24). Treatment by marked, significant (by paired t tests) increases in the
assignments were made blinded to all other aspects of the mean plasma levels of both PLP (49.9%, P 5 0.001)
study. Laboratory analyses, data entry, and data analyses and vitamin B12 (152.4%, P , 0.001) in all 48 subjects.
were performed by code so that treatment assignments Following treatment, both groups evidenced similar,
remained concealed. Compliance with treatment was as- marked elevations in mean plasma total folate [FNA (N 5
sessed by pill counts and determination of the change 24) 5 1371.7 ng/mL; FA (N 5 24) 5 1512.6 ng/mL; P 5
in plasma vitamin status. 0.119 by paired t test].
Nonfasting, prehemodialysis blood samples were col- We have presented results evaluating the between
lected twice before treatment and twice during the 12th groups change in tHcy levels based on the untransformed
week of treatment, as described elsewhere [3]. Plasma continuous variable data only, as use of the transformed
tHcy levels were determined by high-performance liquid data did not alter the findings. There was no significant
chromatography (HPLC) with fluorescence detection [5]. between-group difference in tHcy-lowering treatment
Plasma total folate levels were measured by a microbio- responsiveness (Table 2). Mean percentage (%) reduc-
logical (Lactobacillus casei) assay [6]. Plasma pyridoxal tions (695% CIs) in predialysis tHcy were as follows:
59-phosphate (PLP) levels were measured by radioenzy- FNA group, 22.1% (11.8 to 31.4%); FA group, 20.7%
matic (tyrosine decarboxylase) assay [7], and plasma (11.7 to 30.5%); P 5 0.950. Final on-treatment tHcy
vitamin B12 levels were ascertained by radioassay. To values (mean with 95% CI) were as follows: FNA group,
15.9 mmol/L (14.0 to 18.0); FA group, 16.9 mmol/L (14.8eliminate interassay variability, all analytes were batch
Yango et al: l-folinic acid versus folic acid326
Table 2. Treatment effects to internal validity [9]. Second, several of the subjects
in the study by Touam et al also received high-dose (thatDecrease in tHcy Final tHcy level
Group % lmol/L is, 1 mg/day) oral vitamin B12, and mean levels of vitamin
FNA (N 5 24) 22.1a (11.8–31.4) 15.9a (14.0–18.0) B12 for the entire study group actually doubled over the
FA (N 5 24) 20.7a (11.7–30.5) 16.9a (14.8–18.8) duration of the investigation [4]. Third, the standard
Definitions are: FNA, 20.0 mg l-folinic acid, 50.0 mg vitamin B6, and 1.0 mg daily multivitamin regimen prescribed to essentially all
vitamin B12; FA, 15.0 mg folic acid, 50.0 mg vitamin B6, and 1.0 mg vitamin B12; U.S. hemodialysis patients, including those we studiedtHcy, total homocysteine.
Values are mean (with 95% CI). who complied with the regimen, eliminates potential cases
aP 5 0.950 for between groups difference by paired t test
of folate deficiency and perhaps vitamin B12 deficiency
as well. In contrast, the hemodialysis patients studied by
Touam et al were selected on the basis of either not
receiving, or being noncompliant with, oral FA-based Bto 18.8). Finally, we performed a post hoc, unpaired
vitamin supplementation [4]. Finally, it should be notedanalysis among all patients with pretreatment tHcy levels
that the preliminary uncontrolled data reported by Perna$14 mmol/L (that is, 46 of the total N 5 48). These data
et al in 1997 indicated that two months of oral supple-revealed that neither treatment resulted in “normaliza-
mentation with 5-methyltetrahydrofolate at 15 mg pertion” of tHcy levels (that is, final on-treatment values
day in 10 hemodialysis patients whose pretreatment tHcy,12 mmol/L) among a significantly different or clinically
levels were between approximately 13 and 72 mmol/Lmeaningful number of patients [FNA 5 2 out of 22
caused a mean reduction in their predialysis tHcy levels(9.1%); FA 5 2 out of 24 (8.3%); Fisher’s exact test of
of approximately 61% (that is, from a pretreatment meanbetween groups difference, P 5 1.000].
of ,38 mmol/L to ,15 mmol/L post-treatment) [10]. How-
ever, we recently reported the results from a randomized
DISCUSSION controlled comparison of the tHcy-lowering efficacy of
Our investigation represents the initial controlled com- equimolar amounts of l-5-methyltetrahydrofolate (MTHF;
parison of oral high-dose l-folinic acid [l-5-formyltetra- 17 mg/day) versus FA (15 mg/day)-based B vitamin sup-
hydrofolate] versus equimolar FA-based supplementa- plementation in 50 (that is, two matched groups of 25)
tion for the treatment of mild hyperhomocysteinemia hemodialysis patients [11]. After 12 weeks of treatment,
among chronic, stable hemodialysis patients. Relative to the mean percentage reductions in predialysis tHcy were
FA-based supplementation, we have demonstrated that not significantly different (MTHF, 17.0%; FA, 14.8%;
comparable supraphysiological-dose l-folinic acid-based P 5 0.444) [11].
supplementation does not provide significantly greater Limited experimental observations and human data
reductions in fasting tHcy levels, assessed as either have fostered suggestions that there may be decreased
changes in mean levels, or the proportion of individuals intestinal absorption, as well as general transmembrane
with mild pretreatment hyperhomocysteinemia whose transport of reduced folates, in uremia [12–14]. Livant
tHcy levels were normalized by treatment. The prepon- et al have further speculated that uremia could result in
derance of hemodialysis patients (that is, .90%) who defective folate glutamation [15]. In a recent review, it
were in our study exhibited a mild hyperhomocysteine- was proposed that reduced folate administration could
mia refractory to normalization with either regimen. circumvent these speculative “defects” in folate metabo-
Touam et al, in an open-label, uncontrolled study of 37 lism and more effectively lower tHcy levels in ESRD
hemodialysis patients reported that mean pretreatment compared with FA [16]. Two independent studies by our
tHcy levels of 37.3 mmol/L were lowered to a mean of group, initially involving l-5-MTHF [11] and now l-folinic
12.3 mmol/L post-treatment by administering 50 mg of acid, have provided carefully controlled, definitive evi-
intravenous d,l-folinic acid once per week after dialysis dence that reduced folates afford no improved tHcy-
[4]. In contrast, another uncontrolled study reported by lowering efficacy relative to FA among hemodialysis pa-
Bayes et al revealed that postdialysis treatment with tients. Moreover, elegant folate distribution analyses
10 mg intravenous d,l-5-formyltetrahydrofolate (folinic performed in a subsample of hemodialysis patients from
acid) three times per week (that is, a total of 30 mg/week) our study of MTHF [11] did not support any of the prior
lowered mean tHcy levels to 21 mmol/L post-treatment speculations regarding defective folate metabolism in
from a pretreatment mean of 38 mmol/L (abstract; J Am ESRD [12–16]. Specifically, we observed both normal
Soc Nephrol 10:274A, 1999). Using a controlled design, baseline levels of plasma 5-methyltetrahydrofolate and
we could not confirm the earlier findings by Touam et significant increases in total plasma folate, predomi-
al [4]. There are probably three main reasons for these nantly as plasma 5-methyltetrahydrofolate, after oral
discordant results. First, inflated effect size estimates are treatment with either FA, or l-5-methyltetrahydrofolate
characteristic of the uncontrolled, quasi-experimental de- [11]. In addition, although other tissues were not sam-
pled, normal baseline erythrocyte folate distributionssign employed by Touam et al [4], due to a host of threats
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disease: Probable benefits of increasing folic acid intakes. JAMAwith respect to both methyltetrahydrofolate predomi-
274:1049–1057, 1995
nance and glutamate chain length were observed [11]. 2. Bostom AG, Culleton B: Hyperhomocysteinemia in chronic renal
disease: Disease of the month review. J Am Soc Nephrol 10:891–Moreover, 5-methyltetrahydrofolate monoglutamate was
900, 1999the predominant folate form observed in plasma among
3. Bostom AG, Shemin D, Lapane KL, et al: High dose-B-vitamin
all subjects sampled at baseline and post-treatment [11]. treatment of hyperhomocysteinemia in dialysis patients. Kidney
Int 49:147–152, 1996These findings also help explain the lack of difference in
4. Touam M, Zingraff J, Jungers P, et al: Effective correction oftHcy-lowering efficacy between orally and parenterally
hyperhomocysteinemia in hemodialysis patients by folinic acid and
administered FA in the controlled comparison study re- pyridoxine therapy. Kidney Int 56:2292–2296, 1999
5. Araki A, Sako Y: Determination of free and total homocysteineported by Tremblay et al [17]. Indeed, based on area-
in human plasma by high performance liquid chromatography withunder-the-curve analyses, there is no evidence that par-
fluorescence detection. J Chromatogr 422:43–52, 1987
enteral administration of FA or reduced folates results in 6. Horne DW, Patterson D: Lactobacillus casei assay of folic acid
derivatives in 96-well microtiter plates. Clin Chem 34:2357–2359,greater circulating 5-MTHF levels relative to equimolar
1988administration of oral FA, or reduced folates, such as
7. Shin-Buering Y, Rasshofer R, Endres WA: A new enzymatic
folinic acid [18]. method for pyridoxal 59-phosphate determination. J Inherit Metab
Dis 4:123–124, 1981The folate refractory hyperhomocysteinemia in dial-
8. Dallal GE: PC-Size: A Program for Sample Size Determinationsysis-dependent ESRD may reflect an inability to com-
(version 2.13). Andover, 1986
pensate for losses of normal renal homocysteine uptake 9. Campbell DT, Stanley JC: Experimental and Quasi-Experimental
Designs for Research. Houghton Mifflin College, 1966and metabolism [19, 20], as well as the influence of un-
10. Perna AF, Ingrosso D, De Santo NG, et al: Metabolic conse-identified factors causing extrarenal impairment in homo-
quences of folate-induced reduction of hyperhomocysteinemia in
cysteine metabolism [21, 22]. Data from our earlier study uremia. J Am Soc Nephrol 8:1899–1905, 1997
11. Bostom AG, Shemin D, Bagley P, et al: Controlled comparisonof l-5-MTHF [11], as well as the present study, strongly
of L-5-methyltetrahydrofolate versus folic acid for the treatmentsuggest that defects in folate absorption, or circulating
of hyperhomocysteinemia in hemodialysis patients. Circulation
plasma and tissue distribution, do not contribute to this 101:2829–2832, 2000
12. Said HM, Vaziri ND, Kariger RK, et al: Intestinal absorption ofpersistent hyperhomocysteinemia.
5-methyltetrahydrofolate in experimental uremia. Acta VitaminolIn summary, relative to high dose FA, high-dose oral
Enzymol 6:339–346, 1984
l-folinic acid-based B vitamin supplementation does not 13. Retief FP, Heyns AP, Oosthuizen M, et al: Aspects of folate
metabolism in renal failure. Br J Hematol 36:405–415, 1977afford improved tHcy-lowering efficacy in hemodialysis
14. Jennrette JC, Goldman ID: Inhibition of the membrane transportpatients. The preponderance of hemodialysis patients
of folates by anions retained in uremia. J Clin Lab Med 86:834–843,
(that is, .90%) exhibit mild hyperhomocysteinemia re- 1975
15. Livant EJ, Tamura T, Johnston KE, et al: Plasma folate conjugasefractory to treatment with either regimen.
activities and folate concentrations in patients receiving hemodialy-
sis. J Nutr Biochem 5:504–508, 1994
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